<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sanoudou, D.</style></author><author><style face="normal" font="default" size="100%">Mountzios, G.</style></author><author><style face="normal" font="default" size="100%">Arvanitis, DA</style></author><author><style face="normal" font="default" size="100%">Pectasides, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Array-based pharmacogenomics of molecular-targeted therapies in oncology</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacogenomics JPharmacogenomics JPharmacogenomics J</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The pharmacogenomics journal</style></alt-title><short-title><style face="normal" font="default" size="100%">The pharmacogenomics journalThe pharmacogenomics journal</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Economics, Pharmaceutical</style></keyword><keyword><style  face="normal" font="default" size="100%">*Molecular Targeted Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">*Oligonucleotide Array Sequence Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">*Precision Medicine</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Antineoplastic Agents/*therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Resistance, Neoplasm</style></keyword><keyword><style  face="normal" font="default" size="100%">ErbB Receptors/antagonists &amp; inhibitors/genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling/*methods</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Testing</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms/*drug therapy/genetics/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Patient Selection</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Kinase Inhibitors/*therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Proto-Oncogene Proteins c-kit/antagonists &amp; inhibitors/genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Receptor, ErbB-2/antagonists &amp; inhibitors/genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">185-96</style></pages><isbn><style face="normal" font="default" size="100%">1473-1150 (Electronic)1470-269X (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The advent of microarrays over the past decade has transformed the way genome-wide studies are designed and conducted, leading to an unprecedented speed of acquisition and amount of new knowledge. Microarray data have led to the identification of molecular subclasses of solid tumors characterized by distinct oncogenic pathways, as well as the development of multigene prognostic or predictive models equivalent or superior to those of established clinical parameters. In the field of molecular-targeted therapy for cancer, in particular, the application of array-based methodologies has enabled the identification of molecular targets with 'key' roles in neoplastic transformation or tumor progression and the subsequent development of targeted agents, which are most likely to be active in the specific molecular setting. Herein, we present a summary of the main applications of whole-genome expression microarrays in the field of molecular-targeted therapies for solid tumors and we discuss their potential in the clinical setting. An emphasis is given on deciphering the molecular mechanisms of drug action, identifying novel therapeutic targets and suitable agents to target them with, and discovering molecular markers/signatures that predict response to therapy or optimal drug dose for each patient.</style></abstract><accession-num><style face="normal" font="default" size="100%">22249357</style></accession-num><notes><style face="normal" font="default" size="100%">Sanoudou, DMountzios, GArvanitis, D APectasides, DengResearch Support, Non-U.S. Gov'tReview2012/01/18 06:00Pharmacogenomics J. 2012 Jun;12(3):185-96. doi: 10.1038/tpj.2011.53. Epub 2012 Jan 17.</style></notes><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, Medical School, University of Athens, Athens, Greece. dsanoudo@enders.tch.harvard.edu</style></auth-address></record></records></xml>